◆英語タイトル:National Heart Lung and Blood Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014256
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
National Heart Lung and Blood Institute (NHLBI), a subsidiary of National Institutes of Health is a medical research institute that provides treatment for heart, lung, and blood diseases.The institute conducts research studies with patients who have diseases of heart and blood vessels, lungs, blood cells and bone marrow, and cholesterol. It develops health education and awareness programs to effect positive change in public health. NHLBI operates different divisions for cardiovascular sciences, lung diseases, blood diseases and resources;and a division for intramural research and division for application of research discoveries. The institute works in collaboration with patients, scientists, professional societies, health care professionals, community organizations, and patient advocacy groups. NHLBI is headquartered in Bethesda, Maryland, the US.
National Heart Lung and Blood Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
National Heart Lung and Blood Institute, Medical Devices Deals, 2011 to YTD 2017 9
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 11
Protein Foundry Enters into Research Contract with NHLBI 12
WiCell Research Institute Enters into Distribution Agreement with NHLBI 13
National Heart Lung and Blood Institute – Key Competitors 14
National Heart Lung and Blood Institute – Key Employees 15
National Heart Lung and Blood Institute – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Nov 14, 2017: $8.5M Grant Awarded to Improve Asthma Care with the Navajo Nation 17
Sep 28, 2017: Neuro-Immune Crosstalk in Allergic Asthma 18
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 20
Sep 15, 2017: LSUHealthNO to Study New Drug to Regenerate Heart Muscle 22
Sep 07, 2017: Senators Collins, King Announce $769,681 in Funding to Novo Biosciences for Heart and Vascular Disease Research 23
Oct 28, 2016: Study finds that sleep apnea therapy has positive impact on hypertensive patients 24
Oct 26, 2016: Study Questions Benefits of Long-Term Home Oxygen Therapy for COPD Patients with Moderately Low Blood Oxygen Levels 25
Oct 10, 2016: Doernbecher researchers awarded more than $9 million to fight Fanconi anemia 27
Oct 03, 2016: Study Identifies Risk Factors for Physical Decline Among Survivors of Acute Respiratory Distress Syndrome 28
Sep 30, 2016: NHLBI Awards Grants to Help Improve Health Outcomes for Teens, Adults with Sickle Cell Disease 29
Sep 14, 2016: Allele Receives NIH Award to Fund the Development of Large-Scale Stem Cell Production 30
Apr 27, 2016: New Health Sciences Awarded $3 Million NIH Grant to Commercialize Hemanext 31
Mar 23, 2016: Toward Personalized Medicine for Patients with Cystic Fibrosis 32
Feb 18, 2016: NIH-supported trials test hormonal therapy in older men with low testosterone levels 33
Product News 34
Dec 28, 2016: Fenofibrate May Reduce Heart disease Risk in some Patients with Type 2 Diabetes 34
Jun 13, 2016: Autologous Stem Cell Transplantation Offers Safe and Effective, and Potentially Curative, Option for Patients with HIV-Associated Lymphoma 35
Apr 04, 2016: Antiarrhythmic drugs found beneficial when used by EMS treating cardiac arrest 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Key Facts 2
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
National Heart Lung and Blood Institute, Deals By Therapy Area, 2011 to YTD 2017 8
National Heart Lung and Blood Institute, Medical Devices Deals, 2011 to YTD 2017 9
National Heart Lung and Blood Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 11
Protein Foundry Enters into Research Contract with NHLBI 12
WiCell Research Institute Enters into Distribution Agreement with NHLBI 13
National Heart Lung and Blood Institute, Key Competitors 14
National Heart Lung and Blood Institute, Key Employees 15